廣告
香港股市 已收市

  • 恒指

    18,176.34
    -190.61 (-1.04%)
     

  • 國指

    6,452.06
    -58.31 (-0.90%)
     

  • 上證綜指

    3,028.05
    -23.23 (-0.76%)
     

  • 道指

    38,868.04
    +69.05 (+0.18%)
     

  • 標普 500

    5,360.79
    +13.80 (+0.26%)
     

  • 納指

    17,192.53
    +59.40 (+0.35%)
     

  • Vix指數

    13.15
    +0.41 (+3.22%)
     

  • 富時100

    8,150.70
    -77.78 (-0.95%)
     

  • 紐約期油

    77.43
    -0.31 (-0.40%)
     

  • 金價

    2,331.90
    +4.90 (+0.21%)
     

  • 美元

    7.8107
    -0.0015 (-0.02%)
     

  • 人民幣

    0.9282
    +0.0011 (+0.12%)
     

  • 日圓

    0.0495
    +0.0000 (+0.04%)
     

  • 歐元

    8.3816
    -0.0277 (-0.33%)
     

  • Bitcoin

    66,824.09
    -2,588.45 (-3.73%)
     

  • CMC Crypto 200

    1,390.55
    -51.09 (-3.54%)
     

Myriad (MYGN) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2 分鐘文章

For the quarter ended March 2024, Myriad Genetics (MYGN) reported revenue of $202.2 million, up 11.6% over the same period last year. EPS came in at -$0.01, compared to -$0.21 in the year-ago quarter.

The reported revenue represents a surprise of +4.55% over the Zacks Consensus Estimate of $193.4 million. With the consensus EPS estimate being -$0.11, the EPS surprise was +90.91%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

廣告

Here is how Myriad performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue by Product- Prenatal: $30.90 million compared to the $39.93 million average estimate based on two analysts. The reported number represents a change of -14.6% year over year.

  • Revenue by Product- Hereditary Cancer: $88.10 million compared to the $82.45 million average estimate based on two analysts. The reported number represents a change of +16.4% year over year.

  • Revenue by Product- Pharmacogenomics: $38.90 million compared to the $35.01 million average estimate based on two analysts. The reported number represents a change of +21.6% year over year.

  • Revenue by Product- Tumor Profiling: $30.90 million versus the two-analyst average estimate of $35.96 million. The reported number represents a year-over-year change of -17.2%.

View all Key Company Metrics for Myriad here>>>

Shares of Myriad have returned -1.8% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research